Abstract
This study included 128 patients withcrescentic glomerulonephritis (CGN) havingsufficient clinical and histopathological dataand were followed up in our institute for amean period of 34 ± 28 months. There were 49males and 79 females with mean age 22.7 ± 14years. We studied the effect of clinical,laboratory and histopathological parameters onkidney function and patient survival at the endpoint of the study. The multivariate analysisrevealed that serum creatinine at presentation,nephrotic range proteinuria during the followup period, percentage of glomeruli affected bycrescents, percentage of fibrous crescents andabsence of cellular infiltration weresignificant risk factors affecting the kidneyfunction at termination of the study. The onlyrisk factor which correlated significantly withthe patient mortality was the serum creatinineat last follows up.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rondeau E. Current treatment of crescentic GN. J Nephrol 1993; 6: 14–21.
Couser WG. Idiopathic RPGN. Am J Nephrol 1982; 2: 57–69.
Whitworth JA, Morel-Maroger L, Mignon F et al. The significance of extracapillary proliferation: Clinicopathological review of 60 patients. Nephron 1976; 16: 1–19.
Atkins RC, Kerr PG, Lan HY. Rapidly progressive glomerulonephritis. In: Schrier RW, Gottschalk CW, eds. Diseases of the Kidney. Boston: Little, Brown, 1997; 1617–1644.
Parag KB, Naran AD, Seedat YK et al. Profile of crescentic glomerulonephritis in Natal. Q J Med 1988, 68: 256–236.
Fairley K, Matthews DC, Becker GJ.Rapid development of diffuse crescents in PSGN. Clin. Nephrol 1987; 26: 256–260.
Modai D, Pik A, Behar M. Biopsy proven evolution of PSGN to RPGN. Clin Nephrol 1985; 23: 198–202.
Glassock RJ, Alder SG, Ward HJ, Cohen AH. Primary glomerular diseases. In: Brenner BM, Rector FC Jr, eds. The Kidney, 5th ed. Philadelphia: WB Saunders, 1996: 1392–1497.
Hind CPK, Paraskevakou H, Lockwood CM et al. Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis. Lancet 1983; 1: 263–265.
Neild GH, Cameron JS, OGG CS et al. RPGN with extensive crescent formation. Q J Med 1983; 52: 395–416.
Andrassy K, Kuster S, Waldhern R, Ritz E. RPGN: Analysis of prevalence and clinical course. Nephron 1991; 59: 206–212.
Heilman RL, Offord KP, Holley KE, Velosa JA. Analysis of risk factors for patients and renal survival in crescentic glomerulonephritis. Am J kidney Dis 1987; 9: 98–107.
Stricker GE, Culter RE, Huang TW et al. Glomerulonephritis: Morphology, Natural History and Treatment. New York: Wiley, 1973: 657.
Southwest Pediatric Nephrology Study Group A. Clinicopathologic study of crescentic GN in 50 children. Kidney Int 1985; 27: 450–458.
Hooke DH, Atkins RC. Quantitation of the interstitial leucocyte-infiltration in human GN and interstitial nephritis and the functional significance. (Abstract) IXth International Congress of Nephrology 1984; 283A.
Bhuyan UN, Dash SC, Srivastava RN et al. Immunopathology, extent and course of glomerulonephritis with crescent formation. Clin Nephrol 1982; 18: 280–285.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
El-Husseini, A., El-Agroudy, A., Moustafa, F. et al. Impact of clinical and histopathological factors on outcome of egyptian patients with crescentic glomerulonephritis. Int Urol Nephrol 35, 543–551 (2003). https://doi.org/10.1023/B:UROL.0000025607.41722.aa
Issue Date:
DOI: https://doi.org/10.1023/B:UROL.0000025607.41722.aa